Latest European Market News

Little Green Pharma (ASX:LGP) posted a 15.3% revenue increase to AUD 42.5 million in FY2026, driven by European market expansion, yet recorded a $1.4 million loss after tax impacted by significant inventory write-downs.

Energy One Limited reveals solid sales momentum and strategic AI integration under new CEO Ben Tranier, despite slight ARR timing delays and ongoing market complexity.

Eden Innovations appoints former European Parliament member Antanas Guoga to lead EdenShield’s push into European defence and critical infrastructure markets amid surging regional security spending.

PMET Resources has secured crucial non-binding letters of support from Export Development Canada and Germany’s KfW IPEX-Bank, marking a key step toward financing its Shaakichiuwaanaan critical minerals project in Quebec ahead of an updated feasibility study.

Provaris Energy, alongside Kawasaki Kisen Kaisha (K LINE) and Norwegian Hydrogen, has formalised a cooperation to develop a commercial hydrogen shipping supply chain from Norway to Northern Europe, focusing on cost modelling and charter terms for compressed hydrogen transport.

ALS Limited reported a 25.8% jump in underlying net profit after tax to AUD 381.2 million for FY26, driven by strong commodity testing demand and margin expansion. The company raised its dividend and advanced major hub lab projects while navigating a post-year-end cyber incident.

Evion Group has secured an exclusive option to acquire a high-grade fluorspar project in Nevada, complementing its graphite assets and supported by a $6.5 million capital raise to fund US expansion and exploration.

Bioxyne has locked in a two-year, $50 million exclusive supply agreement with German pharmaceutical distributor ADREXpharma, granting exclusive rights to its Dr Watson® brand in Germany and reinforcing its foothold in Europe’s largest medicinal cannabis market.

Mont Royal Resources reveals one of the largest fluorspar deposits globally at its Ashram Project, supported by historical test work showing high-grade acid-spar concentrate potential and shifting global supply dynamics.

RocketBoots has secured a significant A$3.3 million activation contract with a tier-one multinational retailer and reported over 50% growth in its early sales pipeline, supported by a strong cash position of A$5 million.

Little Green Pharma (ASX:LGP) posted record quarterly and annual revenues driven by a surge in European sales, improved cashflow, and reduced debt. The company is on track to complete its merger with Cannatrek by June 1, 2026, while benefiting from the US rescheduling of medicinal cannabis to Schedule III.

Rhythm Biosciences marked a pivotal shift from development to commercial diagnostics in Q3 FY26, recording its first ColoSTAT® clinical sale and initiating NHS England evaluation while expanding geneType™ partnerships across Asia and Australia.